Virometix Closes Financing Round

Virometix today announced that it has raised CHF 5.0 million in new equity financing to support further development of its vaccine candidates for RSV and cancer immunotherapy. The investment was backed by existing shareholders and new private investors with longstanding experience in the life science sector. Virometix plans to use the new...

read more

Patrick Amstutz Appointed as Chief Executive Officer

Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that the Board of Directors unanimously decided to appoint Patrick Amstutz, Ph.D., co-founder of the company, as Chief Executive Officer and to nominate him to become a member of...

read more

ProteoMediX receives ISO 13485:2012 Certification

ProteoMediX AG, a diagnostic company producing non-invasive in vitro diagnostic assays for prostate cancer diagnosis, has been awarded ISO 13485:2012 certification. ProteoMediX is proud to announce that it has been awarded ISO 13485:2012 certification for the “Design, development, control of production, and distribution of in vitro diagnostics for prostate cancer”. This...

read more